KBC Group
CRL icon

KBC Group’s Charles River Laboratories CRL Stock Holding History

KBC Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$360K Hold
1,588
– – ﹤0.01% 859
2026
Q1 		$274K Buy
1,588
+222
+16% +$41.2K ﹤0.01% 892
2025
Q4 		$272K Hold
1,366
– – ﹤0.01% 812
2025
Q3 		$214K Hold
1,366
– – ﹤0.01% 877
2025
Q2 		$207K Sell
1,366
-74,940
-98% -$9.99M ﹤0.01% 850
2025
Q1 		$11.5M Sell
76,306
-9,056
-11% -$1.52M 0.04% 334
2024
Q4 		$15.8M Buy
85,362
+796
+0.9% +$153K 0.04% 309
2024
Q3 		$16.7M Sell
84,566
-50,319
-37% -$10.5M 0.05% 292
2024
Q2 		$27.9M Sell
134,885
-741
-0.5% -$168K 0.08% 200
2024
Q1 		$36.7M Sell
135,626
-80,013
-37% -$19.1M 0.12% 171
2023
Q4 		$51M Sell
215,639
-2,875
-1% -$565K 0.18% 124
2023
Q3 		$42.8M Buy
218,514
+213,341
+4,124% +$43.8M 0.17% 127
2023
Q2 		$1.09M Buy
5,173
+80
+2% +$15.9K ﹤0.01% 690
2023
Q1 		$1.03M Sell
5,093
-1,738
-25% -$394K ﹤0.01% 716
2022
Q4 		$1.49M Buy
6,831
+3,653
+115% +$798K 0.01% 648
2022
Q3 		$625K Sell
3,178
-19
-0.6% -$4.1K ﹤0.01% 728
2022
Q2 		$684K Buy
3,197
+225
+8% +$55K ﹤0.01% 716
2022
Q1 		$844K Sell
2,972
-65,014
-96% -$20M ﹤0.01% 723
2021
Q4 		$25.6M Sell
67,986
-2,650
-4% -$1.03M 0.08% 232
2021
Q3 		$29.1M Buy
70,636
+62,523
+771% +$26M 0.11% 207
2021
Q2 		$3M Buy
+8,113
New +$2.71M 0.01% 584
2015
Q3 		– Sell
-2,047
Closed -$144K – 1347
2015
Q2 		$144K Sell
2,047
-248
-11% -$18.4K ﹤0.01% 1182
2015
Q1 		$182K Sell
2,295
-877
-28% -$64.7K ﹤0.01% 1143
2014
Q4 		$202K Sell
3,172
-62,561
-95% -$3.92M ﹤0.01% 1190
2014
Q3 		$3.93M Sell
65,733
-5,764
-8% -$330K 0.14% 209
2014
Q2 		$3.83M Buy
+71,497
New +$3.92M 0.04% 444

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

KBC Group's CRL Position: Q2 2026 in Review

KBC Group held its Charles River Laboratories (CRL) position steady in Q2 2026 at 1,588 shares worth $360K. The position accounts for ﹤0.01% of the portfolio, ranked #859.

KBC Group first reported a position in CRL in Q2 2014 and has held it in 26 quarters since. The position peaked at $51M in Q4 2023. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • KBC Group held 1,588 shares of Charles River Laboratories worth $360K as of Q2 2026.
  • KBC Group left its Charles River Laboratories share count unchanged in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #859 holding.
  • KBC Group first reported a position in Charles River Laboratories in Q2 2014 and has held it in 26 quarters since.
  • KBC Group's Charles River Laboratories position peaked at $51M in Q4 2023.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.